Efficacy and safety of verteporfin (Visudyne) in combination with ranibizumab (Lucentis) for the treatment of AMD (Aged-Related Macular Degeneration) (LIV- Lucentis injection with Visudyne).

This study is testing whether combining two treatments — photodynamic therapy (a light-activated treatment) and ranibizumab injections into the eye — works better than injections alone for people with age-related macular degeneration (AMD). AMD is a condition that damages the central part of the retina and can lead to central vision loss. The hope is that the combination may mean fewer injections are needed over time. You may be eligible if: - You are between 50 and 90 years old - You have been diagnosed with AMD causing abnormal blood vessel growth under the retina - Your best corrected vision in the study eye is between 20/40 and 20/320 - You are eligible for photodynamic therapy (Visudyne) in the study eye You may NOT be eligible if: - You have porphyria or a known allergy to verteporfin (the drug used in photodynamic therapy) - You have a history of liver problems or blocked bile ducts - You are pregnant, breastfeeding, or of childbearing age without using contraception - You have previously had photodynamic therapy, radiation, or certain surgeries on the study eye - You have uncontrolled glaucoma, active eye infection, or other significant eye conditions Talk to your doctor about whether this trial might be right for you.